Nymox Reports Third Quarter 2006 Financial Results
HASBROUCK HEIGHTS, N.J.—-Nymox Pharmaceutical Corporation announced today its financial results for the third quarter of 2006. Nymox reported a net loss of $1,238,833, or $0.04 per share for the quarter ending September 30, 2006, compared to $958,464, or $0.04 per share for same period in 2005.
Source: biz.yahoo.com
Spectrum Pharmaceuticals Announces Third Quarter 2006 Financial Results and Pipeline Update
Spectrum Pharmaceuticals, Inc. today reported results for the third quarter ended September 30, 2006.
Source: biz.yahoo.com
AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH
QUEBEC CITY, Nov. 29 /PRNewswire-FirstCall/ — AEterna Zentaris Inc. ( Nachrichten ) (TSX: AEZ; Nasdaq: AEZS) today announced the Company’s plan to initiate its Phase 3 program in benign prostatic hyperplasia (BPH) before year-end with its luteinizing hormone-releasing hormone (LHRH) antagonist compound, cetrorelix, after the Company’s Investigational New Drug Application (IND) was accepted by
Source: www.finanznachrichten.de
Oregon recreation report
The statewide recreation report (for fishing, hunting and viewing), released Wednesday, Nov.8, by the Oregon Department of Fish and Wildlife. Heavy recent rains may have flooded or blown out certain rivers; see below for more details. Streams, tidewaters and bays closed to trout angling Oct. 31.
Source: www.lebanon-express.com
Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way
Prague, Czech Republic: Scientists have found a way of using a protein madeby prostate cancer to target and kill the cancer cells themselves. Inpreliminary studies the new therapy affected only the prostate, withoutcausing damage to other healthy tissues, and now it is being tested in aphase I clinical trial. [click link for full article]
Source: www.medicalnewstoday.com
MCH green-lights laser
Odessans suffering prostate problems no longer have to face prolonged catheterization or long recoveries. Medical Center Hospital is offering a new outpatient option for prostrate enlargement called the Greenlight Laser System.
Source: www.oaoa.com
New Website Tracks Prostate Cancer Research
St. Louis, MO (PRWEB) November 5, 2006 — A new Web site, www.
Source: news.yahoo.com
Agent Orange Harmed Sexual Health of Male Vietnam Vets
DALLAS, Texas , November 15, 2006 (ENS) - A toxic chemical contained in the herbicide Agent Orange affects male reproductive health by limiting the growth of the prostate gland and lowering testosterone levels, researchers have found in a study of more than 2,000 Vietnam War Air Force veterans.
Source: www.ens-newswire.com
New Ultrasound Technique Accurately Distinguishes Benign From Malignant Breast Lesions
A new ultrasound technique allows radiologists to accurately distinguish benign from malignant breast lesions. Using elasticity imaging, researchers correctly identified both cancerous and harmless lesions in nearly all of the cases studied. The findings were presented today at the annual meeting of the Radiological Society of North America.
Source: www.sciencedaily.com
